SCHEMBL24880262

SCHEMBL24880262

CCC(C)N1CCCNC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.37
LMNA P02545 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA3 P07451 1/20 0.35
CA4 P22748 1/20 0.35
CA6 P23280 1/20 0.35
CA5A P35218 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
CA13 Q8N1Q1 1/20 0.35
CA14 Q9ULX7 1/20 0.35
CA5B Q9Y2D0 1/20 0.35
MAPT P10636 1/20 0.35
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14583669 0.88 FAAH (0.35) SMN1; SMN2LMNACA12CA1CA2
SCHEMBL24567501 0.88 FAAH (0.35) SMN1; SMN2LMNACA12CA1CA2
SCHEMBL1106524 0.79 SMN1; SMN2 (0.37) SMN1; SMN2MAPTKDM4EALDH1A1HPGD
SCHEMBL26606698 0.79 LMNA (0.38) SMN1; SMN2LMNACA12CA1CA2
SCHEMBL2610828 0.78 SMN1; SMN2 (0.36) SMN1; SMN2MAPTKDM4EALDH1A1HPGD
SCHEMBL18821387 0.76 SMN1; SMN2 (0.32) SMN1; SMN2MAPT
SCHEMBL10210309 0.76 SMN1; SMN2 (0.35) SMN1; SMN2MAPTKDM4EALDH1A1HPGD
SCHEMBL12512979 0.76 SMN1; SMN2 (0.35) SMN1; SMN2MAPTKDM4EALDH1A1HPGD
SCHEMBL19402861 0.76 SMN1; SMN2 (0.35) SMN1; SMN2MAPTKDM4EALDH1A1HPGD
SCHEMBL18888885 0.75 SMN1; SMN2 (0.31) SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192663-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-06-22 US disclosed
WO-2023283338-A1 PYRIDINONE MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. (US) 2023-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192663-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTSV, CTRL, CTSL SMN1; SMN2 3879/4885LMNA 2696/4885CA12 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.